Trial Profile
Efficacy of enzalutamide following docetaxel and abiraterone in patients with metastatic castrate-resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2016
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Apr 2016 New trial record
- 01 Apr 2016 Results published in the Anticancer Research